6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine | 1267475-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine
• 英文别名: 6-bromo-3-(1-methylpyrazol-4-yl)-5-pyridin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine
• CAS: 1267475-42-2
• 化学式: C₁₅H₁₂BrN₇
• 分子量: 370.211
• InChiKey: HIVMHIQACKWODA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  86.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 生成 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2

  摘要：

  Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo [1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.114

文献信息

• Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2
  作者：Marc Labroli、Kamil Paruch、Michael P. Dwyer、Carmen Alvarez、Kartik Keertikar、Cory Poker、Randall Rossman、Jose S. Duca、Thierry O. Fischmann、Vincent Madison、David Parry、Nicole Davis、Wolfgang Seghezzi、Derek Wiswell、Timothy J. Guzi

  DOI：10.1016/j.bmcl.2010.10.114

  日期：2011.1

  Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo [1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors. (c) 2010 Elsevier Ltd. All rights reserved.